The Apex Times
Above the Noise
Business Wire
BusinessIntel’s push toward on-prem, privacy-focused AI gets a partnership spotlight as Xeon 6 platform work expandsThe Apex TimesBusinessDICK’S Sporting Goods’ guidance cut rattles NIKE, highlighting how weakness at a key specialty retailer can spreadThe Apex TimesBusinessBroadcom (AVGO) set to report earnings Wednesday after the bell, with investors focused on guidance and demand outlinesThe Apex TimesBusinessApple’s John Ternus steps in as investors weigh a valuation-driven “nearly $5 trillion” challengeThe Apex TimesBusinessSalesforce shares jump 22% after results challenge AI skepticism, CNBC’s Jim Cramer saysThe Apex TimesBusinessSeasonality on Wall Street turns investors’ attention to September, with Nvidia and Micron in focusThe Apex TimesBusinessJim Cramer argues Netflix’s valuation should reflect durability despite leadership shake-upThe Apex TimesBusinessNetflix releases a new trailer and key art for ‘The Fixers,’ previewing covert missions in Taiwan’s temple worldThe Apex TimesBusinessLilly’s $2.88 Billion Immunology Acquisition Moves Into Phase 1 as Lead Program Remains EarlyThe Apex TimesBusinessNvidia’s $3.5 Billion Push Highlights a Broader AI Supply-Chain StrategyThe Apex TimesBusinessTesla shares rise after unveiling a cheaper Model 3 in Hong KongThe Apex TimesBusinessAnthropic signs a $35 billion cloud computing deal tied to Nvidia-backed startupThe Apex TimesBusinessIntel’s push toward on-prem, privacy-focused AI gets a partnership spotlight as Xeon 6 platform work expandsThe Apex TimesBusinessDICK’S Sporting Goods’ guidance cut rattles NIKE, highlighting how weakness at a key specialty retailer can spreadThe Apex TimesBusinessBroadcom (AVGO) set to report earnings Wednesday after the bell, with investors focused on guidance and demand outlinesThe Apex TimesBusinessApple’s John Ternus steps in as investors weigh a valuation-driven “nearly $5 trillion” challengeThe Apex TimesBusinessSalesforce shares jump 22% after results challenge AI skepticism, CNBC’s Jim Cramer saysThe Apex TimesBusinessSeasonality on Wall Street turns investors’ attention to September, with Nvidia and Micron in focusThe Apex TimesBusinessJim Cramer argues Netflix’s valuation should reflect durability despite leadership shake-upThe Apex TimesBusinessNetflix releases a new trailer and key art for ‘The Fixers,’ previewing covert missions in Taiwan’s temple worldThe Apex TimesBusinessLilly’s $2.88 Billion Immunology Acquisition Moves Into Phase 1 as Lead Program Remains EarlyThe Apex TimesBusinessNvidia’s $3.5 Billion Push Highlights a Broader AI Supply-Chain StrategyThe Apex TimesBusinessTesla shares rise after unveiling a cheaper Model 3 in Hong KongThe Apex TimesBusinessAnthropic signs a $35 billion cloud computing deal tied to Nvidia-backed startupThe Apex TimesBusinessIntel’s push toward on-prem, privacy-focused AI gets a partnership spotlight as Xeon 6 platform work expandsThe Apex TimesBusinessDICK’S Sporting Goods’ guidance cut rattles NIKE, highlighting how weakness at a key specialty retailer can spreadThe Apex TimesBusinessBroadcom (AVGO) set to report earnings Wednesday after the bell, with investors focused on guidance and demand outlinesThe Apex TimesBusinessApple’s John Ternus steps in as investors weigh a valuation-driven “nearly $5 trillion” challengeThe Apex TimesBusinessSalesforce shares jump 22% after results challenge AI skepticism, CNBC’s Jim Cramer saysThe Apex TimesBusinessSeasonality on Wall Street turns investors’ attention to September, with Nvidia and Micron in focusThe Apex TimesBusinessJim Cramer argues Netflix’s valuation should reflect durability despite leadership shake-upThe Apex TimesBusinessNetflix releases a new trailer and key art for ‘The Fixers,’ previewing covert missions in Taiwan’s temple worldThe Apex TimesBusinessLilly’s $2.88 Billion Immunology Acquisition Moves Into Phase 1 as Lead Program Remains EarlyThe Apex TimesBusinessNvidia’s $3.5 Billion Push Highlights a Broader AI Supply-Chain StrategyThe Apex TimesBusinessTesla shares rise after unveiling a cheaper Model 3 in Hong KongThe Apex TimesBusinessAnthropic signs a $35 billion cloud computing deal tied to Nvidia-backed startupThe Apex TimesBusinessIntel’s push toward on-prem, privacy-focused AI gets a partnership spotlight as Xeon 6 platform work expandsThe Apex TimesBusinessDICK’S Sporting Goods’ guidance cut rattles NIKE, highlighting how weakness at a key specialty retailer can spreadThe Apex TimesBusinessBroadcom (AVGO) set to report earnings Wednesday after the bell, with investors focused on guidance and demand outlinesThe Apex TimesBusinessApple’s John Ternus steps in as investors weigh a valuation-driven “nearly $5 trillion” challengeThe Apex TimesBusinessSalesforce shares jump 22% after results challenge AI skepticism, CNBC’s Jim Cramer saysThe Apex TimesBusinessSeasonality on Wall Street turns investors’ attention to September, with Nvidia and Micron in focusThe Apex TimesBusinessJim Cramer argues Netflix’s valuation should reflect durability despite leadership shake-upThe Apex TimesBusinessNetflix releases a new trailer and key art for ‘The Fixers,’ previewing covert missions in Taiwan’s temple worldThe Apex TimesBusinessLilly’s $2.88 Billion Immunology Acquisition Moves Into Phase 1 as Lead Program Remains EarlyThe Apex TimesBusinessNvidia’s $3.5 Billion Push Highlights a Broader AI Supply-Chain StrategyThe Apex TimesBusinessTesla shares rise after unveiling a cheaper Model 3 in Hong KongThe Apex TimesBusinessAnthropic signs a $35 billion cloud computing deal tied to Nvidia-backed startupThe Apex Times
Back to front
Onsera Health adds Eli Lilly’s oral GLP-1 Foundayo to its personalized cardiometabolic care platform
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 5, 7:09 AM EDT

Onsera Health adds Eli Lilly’s oral GLP-1 Foundayo to its personalized cardiometabolic care platform

The partnership expands Onsera’s injection-free weight and cardiometabolic treatment options by incorporating Eli Lilly’s FDA-approved oral GLP-1 therapy, Foundayo (orforglipron).

By The Apex Times Newsroom3 min readAI-assisted Apex article

Onsera Health said it is strengthening its cardiometabolic care delivery model by adding Eli Lilly’s oral GLP-1 treatment Foundayo (orforglipron) for people living with excess weight. The move is aimed at giving program participants an FDA-approved option that does not require injections, within Onsera’s structured and personalized approach to care.

The announcement, carried by Yahoo Finance, frames Foundayo as an injection-free GLP-1 therapy that can be offered through Onsera’s program design. For Onsera, the emphasis is on delivery and engagement, not just prescribing, with the company positioning its platform as a way to manage weight and related cardiometabolic conditions in a coordinated care setting.

Onsera’s program is described in the post as a “structured personalized care platform.” While the announcement does not provide additional clinical or operational details, the implication is that Onsera is integrating the oral medicine into a broader care workflow, such as ongoing monitoring and individualized support, to help participants stay on treatment.

Eli Lilly’s role in the development of Foundayo is central to the story. In the context of the announcement, Foundayo is presented specifically as an FDA-approved GLP-1 treatment that supports weight management without injections. The shift toward oral GLP-1 options is increasingly relevant for patients who are hesitant about injection-based therapies or who face barriers related to administering them.

Market observers have generally viewed oral GLP-1s as potentially important because they can broaden the addressable audience for incretin-based therapies. Still, it is not clear from the announcement how Onsera expects oral dosing to affect outcomes, adherence rates, or medical utilization compared with injection-based GLP-1s, because those performance details were not disclosed in the post.

Onsera’s decision to bring Foundayo into its delivery platform also highlights how pharmaceutical therapies are increasingly being paired with services and care programs. In many weight-management models, the medication is only one component, and companies are trying to differentiate through patient support, navigation, and structured follow-up. The announcement provides no specific information about program size, pricing, or timelines for rollout.

The companies did not disclose in the Yahoo Finance post the commercial terms of the partnership. There was no information provided on whether Onsera will serve as a care delivery channel for Lilly directly, how long the arrangement runs, or what metrics would define success for the program integration.

What to watch next is whether Onsera expands access beyond any initial participant group and whether Lilly or Onsera later provides data on uptake, patient retention, or clinical endpoints tied to oral therapy within this kind of personalized care program. Until more detail is released, the practical significance of the announcement will likely be measured by adoption and program integration rather than by any reported results in this posting.

Why It Matters

  • Oral GLP-1 options can potentially reduce barriers for patients who prefer not to use injections, which may expand treatment adoption within managed care programs.
  • The integration of a Lilly therapy into a service-delivery model underscores a broader industry trend of pairing chronic disease drugs with coordinated patient support.
  • If Onsera can improve adherence and engagement through structured care, it could influence how payers and providers evaluate weight-management programs.
  • The lack of disclosed commercial terms means investors and industry participants will likely look for later updates on rollout scope and performance indicators.

Sources

Key Facts

  • Onsera Health said it added Eli Lilly’s oral GLP-1 therapy Foundayo (orforglipron) to its cardiometabolic care delivery platform.
  • Foundayo is described as FDA-approved and injection-free in the announcement.
  • Onsera characterized its approach as a structured personalized care platform for people living with excess weight.
  • The announcement does not specify detailed program operations, eligibility criteria, or measurable clinical outcomes.
  • No financial terms or contract details were disclosed in the Yahoo Finance post.

Healthcare Related

Onsera Health adds Eli Lilly’s oral GLP-1 Foundayo to its personalized cardiometabolic care platform | The Apex Times